Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yeah , crazy growth...
Have been inn for many years, didn't expect anything anymore from Mr Govatski,
but positive surprises may also happen from time to time.
Congrats, mr Govatski and team !!
Seems like nothing is in the way north?
market cap after today only 7 mil. imho cap should be at least 75 mil so at least 2.0 a share.
if cash position goes up to $750k....
we have confirmation of a winner.
Super cheap, even with a monster day like this. Wow!! Such great value here with HUGE potential. So glad this this finally popped, much more to come I feel.
wooowwww.......
with a forward looking pe of around 2(current ask 17c).it is cheeeeeeeaaaaapppppp........
1Q results available: net profit of 0.6
This one is going to explode !!!
$NMXS Net Medical Accredited With A+ Rating by the Better Business BureauPress Release | 04/20/2022
ALBUQUERQUE, NM / ACCESSWIRE / April 20, 2022 / Net Medical (OTC PINK:NMXS) announced today that the company has been fully accredited by the Better Business Bureau with an A+ Rating.
A picture containing text, clipartDescription automatically generated
CEO Dick Govatski said, "We welcome the A+ Rating from the Better Business Bureau. It's yet another strong endorsement of our company's high operating standards by a widely respected business group. This is particularly important for a company operating in the medical field."
A Better Business Bureau accreditation is awarded to companies that meet specific standards of honesty and integrity. It is meant to give customers confidence that they are dealing with an ethical and vetted business.
For more information, call 505-255-1999 X 320. Visit www.netmedical.com. Email ir@netmedical.com
About Net Medical - publicly traded (OTC PINK:NMXS) since 1999.
Net Medical Xpress has two operating units. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company specializes in teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare and telenephrology. We maintain a 24/7/365 call center, software developers, and telemedicine platforms. In addition, Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. The company's mobile fleet of vans is utilized to provide statewide COVID and FLU testing for schools, companies, homeless shelters, and nursing homes. The lab also serves as a reference lab for physician offices, and other facilities that lack services for complex virus diagnostics.
Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.
SOURCE: Net Medical Xpress Solutions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/698007/Net-Medical-Accredited-With-A-Rating-by-the-Better-Business-Bureau
$NMXS with news out, A+ rating achieved! https://www.marketwatch.com/press-release/net-medical-accredited-with-a-rating-by-the-better-business-bureau-2022-04-20
$NMXS Net Medical Expands COVID Services With Clinical Trials for ManufacturersPress Release | 04/04/2022
Leaning on two decades of experience connecting providers with the patients who need them, Net Medical's business is unique and growing
ALBUQUERQUE, NM / ACCESSWIRE / April 4, 2022 / Net Medical (OTC PINK:NMXS) announced today it has launched a clinical trial program for medical device manufacturers needing to file an Emergency Use Authorization (EUA) or a 510K clearance with the FDA.
International as well as domestic medical manufacturing companies that want to sell products in the U.S. market are required to file either an EUA or obtain a 510K FDA clearance. An EUA is effective until the circumstances justifying the authorization of the emergency use are terminated by the FDA. At that point, companies must obtain a 510K FDA clearance in order to continue to sell their products.
With the powerful combination of the Net Medical's proprietary Telemed software, a CLIA authorized laboratory and a highly specialized lab staff, Net Medical is particularly well-equipped to implement this program.
Net Medical's Telemed software placed third in the FDA's Designathon contest for COVID-19 reporting in December 2020 out of 731 competing participants including some of the world's best-known companies. This was an important verification and endorsement of the depth and power of Telemed. https://bit.ly/3K6rOxp
Net Medical CEO Dick Govatski said, "With the deep COVID expertise we have acquired over the past two years, Net Medical has developed a highly complex service essential for medical manufacturers to work through a rigorous process of compliance and regulatory hurdles. Telemed provides highly specific data acquisition, management, maintenance and reporting in English and Spanish. As part of the enforcement policy for medical devices under EUA requirements, manufacturers must follow the reporting (MDR) requirements established in 21 CFR Part 803 (Code of Federal Regulations).
"There are few companies like ours able to handle these requirements because of the power of Telemed that enables running clinical trials requiring extensive processing and reporting of complex interrelated activities. We've integrated our telemedicine platform plus a laboratory information system serving the point of care market and the over-thecounter markets. This enables our system to deal with existing and growing Federal regulations and reporting requirements. In addition, our reporting capabilities include a sophisticated Research Use Only (RUO) variant detecting system with the ability to detect multiple variants within a routine COVID test. This is required as part of the trials.
"Net Medical is currently conducting usability studies in English and Spanish as well as a clinical trial for an international COVID test manufacturer. We have additional projects in various stages of development," Govatski said.
For more information, call 505-255-1999. X 320. Visit www.netmedical.com. Email ir@netmedical.com
About Net Medical - publicly traded (OTC Pink: NMXS) since 1999.
Net Medical Xpress has two operating units. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company specializes in teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare and telenephrology. We maintain a 24/7/365 call center, software developers, and telemedicine platforms. In additional, Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. The company's mobile fleet of vans is utilized to provide statewide COVID and FLU testing for schools, companies, homeless shelters, and nursing homes. The lab also serves as a reference lab for physician offices, and other facilities that lack services for complex virus diagnostics.
Forward-Looking Statements. This press release contains forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.
Looking good today. Solid volume, as we hit power hour. Up 16% and over 120k shares traded. News would be great next week to get this over $.10 cents.
Where have all the pumpers gone?
Long time passing.
Where have all the pumpers gone?
Long time ago.
Where have all the pumpers gone?
The other stocks have picked them every one.
Oh, When will you ever learn?
Oh, When will you ever learn?
$NMXS more news in the coming days/weeks. load up!
$NMXS Net Medical Launches Statewide Test-to-Treat COVID TestingPress Release | 03/21/2022
Leaning on two decades of experience connecting providers with the patients who need them, Net Medical's business is unique and growing
ALBUQUERQUE, NM / ACCESSWIRE / March 21, 2022 / Net Medical (OTC PINK:NMXS) announced today it is launching statewide testing in support of the federal government's Test-to-Treat Program.
ShapeDescription automatically generated with medium confidence
Net Medical Chief Medical Officer, Dr. Neeraj Dubey, M.D. said, "While there is a current lull in the pandemic, we are readying a new program to provide a free home telemedicine program to provide both OTC rapid antigen and PCR tests before a new expected surge develops. Our lab technicians will supervise the telemedicine consult to explain how the patient can get a certified CLIA lab result and a consult with our medical staff.
As part of the National COVID-19 Preparedness Plan, and at the first sign of symptoms, a qualified healthcare provider will prescribe antiviral pills from Pfizer and Merck for positive patients who can then pick up the prescription at their preferred pharmacy. This continues our ability to prescribe monoclonal antibodies for severely immunocompromised patients.
The development of oral COVID-19 antivirals could cut the risk of hospitalization and death by nearly 90% according to announcements from Pfizer. In order to qualify, patients must contact Net Medical within the first two days of onset of symptoms. The antiviral drug is most impactful when administered within five days of symptom onset.
Net Medical's Telemed platform will be able to consult patients with our One-Time video link to discuss a patient's history and review results of tests that will be sent out to patients who wish to participate in a convenient, fast, and efficient manner.
Dr. Dubey continued, "We'll initially be targeting patients in Arizona, Pennsylvania and New Mexico. We'll be adding additional states as soon as we train more providers. Our launch will be announced in April."
For more information, call 505-255-1999. X 320. Visit www.netmedical.com. Email ir@netmedical.com
About Net Medical - publicly traded (OTC Pink:NMXS) since 1999.
Net Medical Xpress has two operating units. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company specializes in teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare and telenephrology. We maintain a 24/7/365 call center, software developers, and telemedicine platforms. In additional, Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. The company's mobile fleet of vans is utilized to provide statewide COVID and FLU testing for schools, companies, homeless shelters, and nursing homes. The lab also serves as a reference lab for physician offices, and other facilities that lack services for complex virus diagnostics.
Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.
Net Medical's Telemed platform will be able to consult patients with our One-Time video link to discuss a patient's history and review results of tests that will be sent out to patients who wish to participate in a convenient, fast, and efficient manner.
$NMXS
Net Medical Chief Medical Officer, Dr. Neeraj Dubey, M.D. said, "While there is a current lull in the pandemic, we are readying a new program to provide a free home telemedicine program to provide both OTC rapid antigen and PCR tests before a new expected surge develops. Our lab technicians will supervise the telemedicine consult to explain how the patient can get a certified CLIA lab result and a consult with our medical staff. $nmxs
#BreakingNews: $NMXS Net Medical Launches Statewide Test-to-Treat COVID Testing @jctb1 https://finance.yahoo.com/news/net-medical-launches-statewide-test-123000564.html
$NMXS #BreakingNews - Net Medical Launches Statewide Test-to-Treat COVID Testing
Leaning on two decades of experience connecting providers with the patients who need them, Net Medical's business is unique and growing
ALBUQUERQUE, NM / ACCESSWIRE / March 21, 2022 / Net Medical (OTC PINK:NMXS) announced today it is launching statewide testing in support of the federal government's Test-to-Treat Program. https://finance.yahoo.com/news/net-medical-launches-statewide-test-123000564.html
Nice year over year increase in revenue
$NMXS announced revenues in 2021 of $1.768 million verses revenues of $1,118,000 in 2020. @jctb1 https://finance.yahoo.com/news/net-medical-reports-improved-financial-123000891.html
Interesting question... hopefully $NMXS can shed some light on this, or someone else who understands this better than me.))))
ooopppp...
correction:
"but
cash down to 350k
ar up to 400k(1183k before a 783k adjustment) from 185k.ouchhhhh."
to:
"but
cash down 350k
ar up 400k(1183k before a 783k adjustment) from 185k.ouchhhhh."
was 2/22/2022 pr totally misleading...........
and turned us into suckers!
2/22/2022 pr release:
"Net Medical Xpress Solutions (OTC PINK:NMXS) said today that unaudited preliminary numbers show the company recorded net income of $301,285 in the fourth fiscal quarter ending December 31, 2021. Total revenue was $821,399."
without disclosing
"medical billing allowance of $783,000",and later added to the fourth fiscal quarter on 3/11/2022.
my concern:
3q cash/ar 946k(761k+185k)
vs
4q cash/ar 1017k(411k+606k)
or
q/q change:
income increased to 301k
but
cash down to 350k
ar up to 400k(1183k before a 783k adjustment) from 185k.ouchhhhh.
is nmxs padding its topline at the expense of abnormal ar write down(and unable to collect)?
does this seem right(too much)?
from https://www.otcmarkets.com/otcapi/company/financial-report/323348/content
concern:
account receivable,net of allowance of $24,000 and medical billing allowance of $783,000,.......
company argument:
"The Company estimates an allowance for doubtful medical billing, which amount to $783,000 and $0 at
December 31, 2021 and 2020, respectively. The Company started performing Covid-19 testing in 2021 and
therefore medical billing did not begin until 2021. The estimate is based upon management’s review of medical
billing accounts and an assessment of the Company’s historical evidence of medical billing collections."
is $783k recoverable/reversible(likely) in 2022 or all gone for good??
$NMXS "As 2022 is unfolding, we are exploring additional testing programs, expansion into related operations and additional geographic areas of operations. For instance, we are actively investigating whether our mobile testing labs can actively support the Federal government's just announced Test to Treat program, whereby a patient diagnosed with certain illness can be immediately prescription treated. The connection of our vans directly to one of our qualified physicians makes this possible. We also expect shortly to be able to simultaneously provide both PCR and Antigen testing. I expect to have more to say about this in the future," Govatski said.
$NMXS Net Medical CEO Dick Govatski said, "We were pleased to record improved financial results for 2021. Revenues were up 58% and we were profitable for the year. We benefited from new revenue from our medical laboratory services that we believe position us for an even better year in 2022.
#BreakingNews: $NMXS Net Medical Reports Improved Financial Results For 2021 @jctb1 https://finance.yahoo.com/news/net-medical-reports-improved-financial-123000891.html
Thanks, just saw those. I'll check out the article a bit later.
$NMXS Net Medical Xpress Solutions reports FY results
https://seekingalpha.com/news/3813102-net-medical-xpress-solutions-reports-fy-results?utm_source=advfn.com&utm_medium=referral
$NMXS trading green as volume picked up a little bit...
$NMXS Strong buy up 72% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal. https://www.barchart.com/stocks/quotes/NMXS/opinion
That's an interesting thought. We shall see what happens in the next few months. $NMXS
i guess wager on the covid is on its way out.......
along with covid related services and replaced with energy/commodities play.
ps-a covid(or soldier) never dies it just fades away.
too bad nobody is buying this dead beat POS
Net Medical CEO Dick Govatski said, "Demand was high for Covid tests provided through our state-of-the-art mobile testing labs. Our patients benefited from our use of bioMerieux's proprietary PCR testing module that provides quick certified results that can be used for travel and other purposes. It is the only FDA approved test that can detect and identify 22 separate viral pathogens including Covid, influenza and the common cold." $NMXS
Net Medical CEO Dick Govatski said, "The Covid pandemic has created new awareness about both the need and ability of individuals to take steps to protect their own health. The rapid growth of our Covid testing business has introduced us to a large underserved market of consumers who have a fresh awareness of the threats to their health.
$NMXS
Weird that $NMXS is trading such low volume.
Looking forward to seeing future updates from $NMXS on this front.
$NMXS 100% Strong buy average @barchart https://www.barchart.com/stocks/quotes/NMXS/opinion
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
792
|
Created
|
02/13/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |